Rodeo Therapeutics

Rodeo Therapeutics is a biotechnology company that specializes in developing small molecule therapies designed to promote the regeneration and repair of various tissues. The company's proprietary platform focuses on inhibiting 15-prostaglandin dehydrogenase (15-PGDH), an enzyme responsible for the degradation of prostaglandins which are essential for tissue maintenance and healing. By increasing levels of Prostaglandin E2, Rodeo's lead programs aim to treat inflammatory bowel disease, idiopathic pulmonary fibrosis, and accelerate hematopoietic stem cell reconstitution. Founded in 2017 and based in Seattle, the company was built on research from Case Western Reserve University and UT Southwestern Medical Center. In March 2021, Rodeo was acquired by Amgen for an upfront payment of 55 million USD plus significant future milestones.